<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774512458993</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774512458993</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Data Management and Trial Conduct</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A systematic search for reports of site monitoring technique comparisons in clinical trials</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bakobaki</surname><given-names>Julie</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512458993">a</xref>
<xref ref-type="aff" rid="aff2-1740774512458993">b</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Joffe</surname><given-names>Nicola</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512458993">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Burdett</surname><given-names>Sarah</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512458993">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tierney</surname><given-names>Jayne</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512458993">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Meredith</surname><given-names>Sarah</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512458993">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stenning</surname><given-names>Sally</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512458993">a</xref>
</contrib>
</contrib-group>
<aff id="aff1-1740774512458993"><label>a</label>Medical Research Council (MRC) Clinical Trials Unit Hub for Trials Methodology Research, London, UK</aff>
<aff id="aff2-1740774512458993"><label>b</label>University College London Clinical Trials Unit, London, UK</aff>
<author-notes>
<corresp id="corresp1-1740774512458993">Julie Bakobaki, University College London Clinical Trials Unit, Gower Street, London, WC1E 6BT, UK. Email: <email>j.bakobaki@ucl.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>9</volume>
<issue>6</issue>
<issue-title>University of Pennsylvania Conference on Statistical Issues in Clinical Trials: Emerging statistical issues in the conduct and monitoring of clinical trials</issue-title>
<fpage>777</fpage>
<lpage>780</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1740774512458993">
<title>Background</title>
<p>As part of a broader methodological programme of work around clinical trial monitoring, we wanted to evaluate the existing evidence for the effectiveness of different monitoring techniques.</p>
</sec>
<sec id="section2-1740774512458993">
<title>Purpose</title>
<p>To identify and evaluate prospective studies of the effectiveness of different monitoring strategies.</p>
</sec>
<sec id="section3-1740774512458993">
<title>Methods</title>
<p>A systematic search of MEDLINE from 1950 onwards, using free-text terms to identify relevant published studies. We intended to extract data on details of comparative techniques, monitoring findings identified by different techniques, and recommendations or identification of areas in need of further research made by authors.</p>
</sec>
<sec id="section4-1740774512458993">
<title>Results</title>
<p>A total of 1222 published abstracts were identified and reviewed. Of these, nine articles described methods for quality control (QC) of clinical trial activities, and one article was identified that compared the same monitoring technique at two timepoints. None included a direct comparison of different monitoring techniques and findings.</p>
</sec>
<sec id="section5-1740774512458993">
<title>Limitations</title>
<p>The search strategy was limited to MEDLINE. However, MEDLINE includes all the journals that tend to report trial methodological research.</p>
</sec>
<sec id="section6-1740774512458993">
<title>Conclusions</title>
<p>There is a lack of published empirical data that compare monitoring strategies prospectively. Assessment of the usefulness and cost-effectiveness of monitoring techniques in a variety of clinical trial settings and indications is needed.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="section7-1740774512458993" sec-type="intro">
<title>Introduction</title>
<p>There is a growing consensus that the interpretation and application of regulatory guidelines governing clinical trials of medicines in humans have increased the cost and complexity of clinical trials [<xref ref-type="bibr" rid="bibr1-1740774512458993">1</xref><xref ref-type="bibr" rid="bibr2-1740774512458993"/><xref ref-type="bibr" rid="bibr3-1740774512458993"/>–<xref ref-type="bibr" rid="bibr4-1740774512458993">4</xref>]. The objectives of good clinical practice (GCP; i.e., the protection of the safety and rights of study participants and the maintenance of data reliability) remain sound [<xref ref-type="bibr" rid="bibr5-1740774512458993">5</xref>]. Methods used to demonstrate compliance, that is, through on-site trial monitoring, have been described in some detail [<xref ref-type="bibr" rid="bibr1-1740774512458993">1</xref>,<xref ref-type="bibr" rid="bibr6-1740774512458993">6</xref><xref ref-type="bibr" rid="bibr7-1740774512458993"/><xref ref-type="bibr" rid="bibr8-1740774512458993"/>–<xref ref-type="bibr" rid="bibr9-1740774512458993">9</xref>]. However, there remains a lack of empirical evidence to demonstrate the most appropriate methods of trial monitoring for cost-effective mitigation of problems sufficiently early for modification of procedures, or provision of training or support, to have a positive impact on study participation, conduct, or outcomes.</p>
<p>Intensive ‘on-site’ monitoring has become a standard practice for many organisations involved in conducting clinical research. Such monitoring tends to include source data verification; site master file review; a review of participant consent forms; review of endpoint, event, and accountability data; and the discussion of trial processes and activity with site teams, to ascertain that the protocol, GCP, and applicable local and national guidelines are being followed. Central monitoring of the trial data and procedures (similar processes with the same aims in mind but conducted from a central coordinating unit rather than on-site) offers an alternative (or additional activities) that may require considerably fewer resources, particularly in the case of multi-centre and international trials. We conducted a systematic search of MEDLINE to identify published studies of empirically tested clinical trial monitoring techniques and their results.</p>
<p>As background research for a broader methodological programme of work around trial monitoring [<xref ref-type="bibr" rid="bibr10-1740774512458993">10</xref>], we conducted a systematic search of the literature to identify studies comparing different monitoring strategies or comparing central and on-site monitoring techniques in clinical trials. We sought comparisons that took place within a randomised trial of a therapy (as these are the typical studies where compliance with GCP is required to be demonstrated). However, the groups exposed to the different monitoring strategies being compared need not have been randomised. We considered that the introduction of, or changes to, monitoring was likely to have been implemented in many trials as a result of the changes to clinical trials guidelines since 1990. It was also judged likely that most comparisons between different practices would be reported in trials published since 2005, subsequent to the European Union (EU) Clinical Trials Directive becoming law in all European member states in 2004 [<xref ref-type="bibr" rid="bibr11-1740774512458993">11</xref>]. However, we looked prior to this date to take account of potential exploratory work and to get a wider feel of earlier scientific opinion. The research team was of the opinion that few, if any, published studies would be available and, therefore, that the number of relevant publications identified by the search would be low. As MEDLINE contains a large majority of the journals that tend to publish trial methodological research, we made an a priori decision to restrict our search to MEDLINE.</p>
</sec>
<sec id="section8-1740774512458993" sec-type="methods">
<title>Methods</title>
<p>We searched MEDLINE systematically from 1950 onwards, using free-text terms to identify relevant published studies (<xref ref-type="fig" rid="fig1-1740774512458993">Figure 1</xref>). We planned to extract descriptive data of comparative monitoring techniques and strategies, details of the proportion of monitoring findings identified by different techniques, and details of recommendations made or identification of further research areas by the authors.</p>
<fig id="fig1-1740774512458993" position="float">
<label>Figure 1.</label>
<caption>
<p>MEDLINE search strategy.</p>
</caption>
<graphic xlink:href="10.1177_1740774512458993-fig1.tif"/>
</fig>
<p>In developing the search strategy, we excluded a number of terms that generated an excessive amount of irrelevant articles, including the more general terms: data management, data monitoring committee, data safety and monitoring board, and blood pressure monitoring.</p>
</sec>
<sec id="section9-1740774512458993" sec-type="results">
<title>Results</title>
<p>Our final search strategy identified 1222 published titles and abstracts; these were reviewed by two authors independently. Of these, nine articles described methods for quality control (QC) of clinical trial activities in varying levels of detail [<xref ref-type="bibr" rid="bibr12-1740774512458993">12</xref><xref ref-type="bibr" rid="bibr13-1740774512458993"/><xref ref-type="bibr" rid="bibr14-1740774512458993"/><xref ref-type="bibr" rid="bibr15-1740774512458993"/><xref ref-type="bibr" rid="bibr16-1740774512458993"/><xref ref-type="bibr" rid="bibr17-1740774512458993"/><xref ref-type="bibr" rid="bibr18-1740774512458993"/><xref ref-type="bibr" rid="bibr19-1740774512458993"/>–<xref ref-type="bibr" rid="bibr20-1740774512458993">20</xref>]; one article was identified that compared the same monitoring technique (individual case reviews of compliance with the protocol and with quality of reporting of data from source data verification) applied early in the conduct of and again near to the end of the trial [<xref ref-type="bibr" rid="bibr21-1740774512458993">21</xref>]. No publication reported a direct comparison of different monitoring techniques and findings.</p>
<p>We are aware of four additional publications that describe ways of reducing clinical trial costs through a risk-based and targeted approach to monitoring [<xref ref-type="bibr" rid="bibr2-1740774512458993">2</xref><xref ref-type="bibr" rid="bibr3-1740774512458993"/><xref ref-type="bibr" rid="bibr4-1740774512458993"/>–<xref ref-type="bibr" rid="bibr4-1740774512458993">4</xref>,<xref ref-type="bibr" rid="bibr6-1740774512458993">6</xref>]. Two of these articles [<xref ref-type="bibr" rid="bibr4-1740774512458993">4</xref>,<xref ref-type="bibr" rid="bibr6-1740774512458993">6</xref>] were published after our search was conducted. The other two [<xref ref-type="bibr" rid="bibr2-1740774512458993">2</xref>,<xref ref-type="bibr" rid="bibr3-1740774512458993">3</xref>] were not identified by our search terms; furthermore, based on the titles and abstracts, we could not see how usefully we could have broadened our search terms in order to identify them in the search. None of the four publications included direct comparison of monitoring techniques within randomised trials.</p>
<p>Results are expected in 2014 from a prospective study called Targeted Monitoring, Prospective Evaluation and Refinement (TEMPER), which evaluates a triggered on-site monitoring strategy for multi-centre cancer clinical trials (<ext-link ext-link-type="uri" xlink:href="http://www.ctu.mrc.ac.uk/research_areas/methodology/trial_conduct_methodology/trial_monitoring/prospective_evaluation.aspx">http://www.ctu.mrc.ac.uk/research_areas/methodology/trial_conduct_methodology/trial_monitoring/prospective_evaluation.aspx</ext-link>). The TEMPER study aims to establish whether a targeted on-site monitoring strategy identifies sites with a higher rate of major/critical findings at on-site visits, compared with untriggered sites, and may therefore be a useful monitoring strategy. The study will use a prospective matched-pair design to assess the targeted monitoring strategy currently being used at the Medical Research Council Clinical Trials Unit (MRC CTU) by comparing monitoring findings in targeted versus non-targeted sites.</p>
<p>Personal communications during the discussion of this search also meant that we became aware of a prospective, randomised monitoring sub-study within a clinical trial of the strategic timing of anti-retroviral therapy (the Strategic Timing of AntiRetroviral Treatment-International Network for Strategic Initiatives in Global HIV Trials (START INSIGHT) trial (<ext-link ext-link-type="uri" xlink:href="http://insight.ccbr.umn.edu/start/">http://insight.ccbr.umn.edu/start/</ext-link>)). The sub-study, which began in September 2011, aims to determine whether the addition of on-site monitoring to central and local monitoring is superior to central and local monitoring alone.</p>
</sec>
<sec id="section10-1740774512458993" sec-type="conclusions">
<title>Conclusion</title>
<p>Our conclusion from this systematic search is that there is a lack of published empirical data that compare monitoring strategies prospectively. Assessment of the usefulness and cost-effectiveness of monitoring techniques in a variety of clinical trial settings and indications is needed.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by the MRC Clinical Trials Unit Hub for Trials Methodology Research (MRC grant number G0800814).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare that there is no commercial or financial conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774512458993">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baigent</surname><given-names>C</given-names></name>
<name><surname>Harrell</surname><given-names>F</given-names></name>
<name><surname>Buyse</surname><given-names>M</given-names></name>
<name><surname>Emberson</surname><given-names>J</given-names></name>
<name><surname>Altman</surname><given-names>D</given-names></name>
</person-group>. <article-title>Ensuring trial validity by data quality assurance and diversification of monitoring methods</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>(<issue>1</issue>): <fpage>49</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr2-1740774512458993">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eisenstein</surname><given-names>E</given-names></name>
<name><surname>Collins</surname><given-names>R</given-names></name>
<name><surname>Cracknell</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Sensible approaches for reducing clinical trial costs</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>: <fpage>75</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr3-1740774512458993">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glickman</surname><given-names>S</given-names></name>
<name><surname>McHutchison</surname><given-names>J</given-names></name>
<name><surname>Peterson</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Ethical and scientific implications of the globalisation of clinical research</article-title>. <source>N Engl J Med</source> <year>2009</year>; <volume>360</volume>(<issue>8</issue>): <fpage>816</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr4-1740774512458993">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pronker</surname><given-names>E</given-names></name>
<name><surname>Geerts</surname><given-names>B</given-names></name>
<name><surname>Cohen</surname><given-names>A</given-names></name>
<name><surname>Pieterse</surname><given-names>H</given-names></name>
</person-group>. <article-title>Improving the quality of drug research or simply increasing its cost? An evidence-based study of the cost for data monitoring in clinical trials</article-title>. <source>Br J Clin Pharmacol</source> <year>2011</year>; <volume>71</volume>(<issue>3</issue>): <fpage>467</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr5-1740774512458993">
<label>5.</label>
<citation citation-type="web">
<collab>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use</collab>. <article-title>ICH harmonised tripartite guidelines</article-title>. <source>Guideline for good clinical practice E6, R1</source>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf">http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf</ext-link> (<access-date>accessed 13 September 2011</access-date>).</citation>
</ref>
<ref id="bibr6-1740774512458993">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrison</surname><given-names>B</given-names></name>
<name><surname>Cochran</surname><given-names>C</given-names></name>
<name><surname>White</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Monitoring the quality of conduct of clinical trials: A survey of current practices</article-title>. <source>Clin Trials</source> <year>2011</year>; <volume>8</volume>: <fpage>342</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr7-1740774512458993">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duley</surname><given-names>L</given-names></name>
<name><surname>Antman</surname><given-names>K</given-names></name>
<name><surname>Arena</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Specific barriers to the conduct of randomised trials</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>: <fpage>40</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr8-1740774512458993">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yusuf</surname><given-names>S</given-names></name>
<name><surname>Bosch</surname><given-names>J</given-names></name>
<name><surname>Devereaux</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Sensible guidelines for the conduct of large randomised trials</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>: <fpage>38</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr9-1740774512458993">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Califf</surname><given-names>R</given-names></name>
</person-group>. <article-title>Clinical trials bureaucracy: Unintended consequences of well-intentioned policy</article-title>. <source>Clin Trials</source> <year>2006</year>; <volume>3</volume>: <fpage>496</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr10-1740774512458993">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakobaki</surname><given-names>J</given-names></name>
<name><surname>Rauchenberger</surname><given-names>M</given-names></name>
<name><surname>Joffe</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>The potential for central monitoring techniques to replace on-site monitoring: Findings from an international multi-centre clinical trial</article-title>. <source>Clin Trials</source> <year>2012</year>; <volume>9</volume>: <fpage>257</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr11-1740774512458993">
<label>11.</label>
<citation citation-type="journal">
<collab>Directive 2001/20/EC of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good practice in the conduct of clinical trials on medicinal products for human use</collab>. <source>Official Journal L</source> <year>2001</year>; <volume>121</volume>: <fpage>0034</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr12-1740774512458993">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grimes</surname><given-names>D</given-names></name>
<name><surname>Hubacher</surname><given-names>D</given-names></name>
<name><surname>Nanda</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>The good clinical practice guideline: A bronze standard for clinical research</article-title>. <source>Lancet</source> <year>2005</year>; <volume>366</volume>: <fpage>172</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr13-1740774512458993">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Journot</surname><given-names>V</given-names></name>
<name><surname>Pignon</surname><given-names>JP</given-names></name>
<name><surname>Gaultier</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>On behalf of the Optimon Collaborative Group. Validation of a risk assessment scale and a risk-adapted monitoring plan for academic clinical research studies – The Pre-Optimon Study</article-title>. <source>Contemp Clin Trials</source> <year>2010</year>; doi: <pub-id pub-id-type="doi">10.1016/j.cct.2010.10.001</pub-id> (Epub ahead print).</citation>
</ref>
<ref id="bibr14-1740774512458993">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brosteanu</surname><given-names>O</given-names></name>
<name><surname>Houben</surname><given-names>P</given-names></name>
<name><surname>Ihrig</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Risk analysis and risk adapted on-site monitoring in non-commercial clinical trials</article-title>. <source>Clin Trials</source> <year>2009</year>; <volume>6</volume>: <fpage>585</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr15-1740774512458993">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirwan</surname><given-names>B</given-names></name>
<name><surname>Lubsen</surname><given-names>J</given-names></name>
<name><surname>de Brouwer</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Quality management of a large randomised double-blind multi-centre trial: The ACTION experience</article-title>. <source>Contemp Clin Trials</source> <year>2008</year>; <volume>29</volume>(<issue>2</issue>): <fpage>259</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr16-1740774512458993">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liénard</surname><given-names>JL</given-names></name>
<name><surname>Quinaux</surname><given-names>E</given-names></name>
<name><surname>Fabre-Guillevin</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>On behalf of the European Association for Research in Oncology. Impact of on-site initiation visits on patient recruitment and data quality in a randomised trial of adjuvant chemotherapy for breast cancer</article-title>. <source>Clin Trials</source> <year>2006</year>; <volume>3</volume>(<issue>5</issue>): <fpage>486</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr17-1740774512458993">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>G</given-names></name>
</person-group>. <article-title>The other side of clinical trial monitoring; assuring data quality and procedural adherence</article-title>. <source>Clin Trials</source> <year>2006</year>; <volume>3</volume>(<issue>6</issue>): <fpage>530</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr18-1740774512458993">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sather</surname><given-names>M</given-names></name>
<name><surname>Raisch</surname><given-names>D</given-names></name>
<name><surname>Haakenson</surname><given-names>C</given-names></name>
<name><surname>Beckelew</surname><given-names>J</given-names></name>
<name><surname>Feussner</surname><given-names>J</given-names></name>
</person-group>. <article-title>Promoting good clinical practices in the conduct of clinical trials: Experiences in the Department of Veterans Affairs Cooperative Studies Program</article-title>. <source>Control Clin Trials</source> <year>2003</year>; <volume>24</volume>(<issue>5</issue>): <fpage>570</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr19-1740774512458993">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cassel</surname><given-names>G</given-names></name>
<name><surname>Ferris</surname><given-names>FL</given-names></name>
</person-group>. <article-title>Site visits in a multicentre ophthalmic clinical trial</article-title>. <source>Control Clin Trials</source> <year>1984</year>; <volume>5</volume>(<issue>3</issue>): <fpage>251</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr20-1740774512458993">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gassman</surname><given-names>J</given-names></name>
<name><surname>Owen</surname><given-names>W</given-names></name>
<name><surname>Kunts</surname><given-names>T</given-names></name>
<name><surname>Martin</surname><given-names>J</given-names></name>
<name><surname>Amoroso</surname><given-names>W</given-names></name>
</person-group>. <article-title>Data quality assurance, monitoring and reporting</article-title>. <source>Control Clin Trials</source> <year>1995</year>; <volume>16</volume>(<supplement>2 Suppl</supplement>): <fpage>104</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr21-1740774512458993">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poortmans</surname><given-names>P</given-names></name>
<name><surname>Ataman</surname><given-names>F</given-names></name>
<name><surname>Davis</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Quality assurance in the EORTC phase III randomised ‘boost vs. no boost’ trial for breast conserving therapy: Comparison of the results of two individual case reviews performed early and late during the accrual period</article-title>. <source>Radiother Oncol</source> <year>2005</year>; <volume>76</volume>(<issue>3</issue>): <fpage>278</fpage>–<lpage>84</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>